Unité de Médecine Intensive et Réanimation Polyvalente, CHU Reims, Reims, F-51100, France.
Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nice, Hôpital l'Archet 1, Nice, France.
Respir Res. 2024 Jul 15;25(1):279. doi: 10.1186/s12931-024-02873-4.
We assessed the effect of noninvasive ventilation (NIV) on mortality and length of stay after high flow nasal oxygenation (HFNO) failure among patients with severe hypoxemic COVID-19 pneumonia.
In this multicenter, retrospective study, we enrolled COVID-19 patients admitted in intensive care unit (ICU) for severe COVID-19 pneumonia with a HFNO failure from December 2020 to January 2022. The primary outcome was to compare the 90-day mortality between patients who required a straight intubation after HFNO failure and patients who received NIV after HFNO failure. Secondary outcomes included ICU and hospital length of stay. A propensity score analysis was performed to control for confounding factors between groups. Exploratory outcomes included a subgroup analysis for 90-day mortality.
We included 461 patients with HFNO failure in the analysis, 233 patients in the straight intubation group and 228 in the NIV group. The 90-day mortality did not significantly differ between groups, 58/228 (25.4%) int the NIV group compared with 59/233 (25.3%) in the straight intubation group, with an adjusted hazard ratio (HR) after propensity score weighting of 0.82 [95%CI, 0.50-1.35] (p = 0.434). ICU length of stay was significantly shorter in the NIV group compared to the straight intubation group, 10.0 days [IQR, 7.0-19.8] versus 18.0 days [IQR,11.0-31.0] with a propensity score weighted HR of 1.77 [95%CI, 1.29-2.43] (p < 0.001). A subgroup analysis showed a significant increase in mortality rate for intubated patients in the NIV group with 56/122 (45.9%), compared to 59/233 (25.3%) for patients in the straight intubation group (p < 0.001).
In severely hypoxemic COVID-19 patients, no significant differences were observed on 90-day mortality between patients receiving straight intubation and those receiving NIV after HFNO failure. NIV strategy was associated with a significant reduction in ICU length of stay, despite an increase in mortality in the subgroup of patients finally intubated.
我们评估了无创通气(NIV)对高流量鼻氧疗(HFNO)失败后严重低氧血症 COVID-19 肺炎患者死亡率和住院时间的影响。
在这项多中心回顾性研究中,我们招募了因严重 COVID-19 肺炎而在重症监护病房(ICU)接受 HFNO 治疗失败的 COVID-19 患者。主要结局是比较 HFNO 失败后直接插管患者与 HFNO 失败后接受 NIV 患者的 90 天死亡率。次要结局包括 ICU 和住院时间。进行倾向评分分析以控制组间混杂因素。探索性结局包括 90 天死亡率的亚组分析。
我们对 461 例 HFNO 失败患者进行了分析,233 例患者在直接插管组,228 例患者在 NIV 组。两组 90 天死亡率无显著差异,NIV 组 58/228(25.4%)与直接插管组 59/233(25.3%),经倾向评分加权后调整后的危险比(HR)为 0.82[95%CI,0.50-1.35](p=0.434)。与直接插管组相比,NIV 组 ICU 住院时间明显缩短,10.0 天[IQR,7.0-19.8]与 18.0 天[IQR,11.0-31.0],经倾向评分加权后的 HR 为 1.77[95%CI,1.29-2.43](p<0.001)。亚组分析显示,NIV 组插管患者死亡率显著升高,56/122(45.9%),而直接插管组患者死亡率为 59/233(25.3%)(p<0.001)。
在严重低氧血症 COVID-19 患者中,HFNO 失败后接受直接插管与接受 NIV 的患者 90 天死亡率无显著差异。尽管最终插管患者亚组死亡率增加,但 NIV 策略与 ICU 住院时间显著缩短相关。